NCT05621148View on ClinicalTrials.gov

REfractorinesS to Ibrutinib BTKi and Systemic Targeted Therapy

CompletedOBSERVATIONAL
Enrollment

152

Participants

Timeline

Start Date

January 25, 2023

Primary Completion Date

December 31, 2023

Study Completion Date

March 31, 2024

Conditions
CLL, RelapsedCLL, RefractoryBruton Tyrosine Kinase InhibitorSmall Lymphocytic Leukemia
Trial Locations (8)

13273

Institut Paoli-Calmettes - Hématologie Clinique, Marseille

31059

Toulouse - IUCT Oncopole - Service d'Hématologie, Toulouse

33604

Bordeaux Pessac, Pessac

34295

MONTPELLIER - Hôpital Saint-Eloi - Hématologie Clinique, Montpellier

63000

CHU Estaing - Hématologie Clinique Adulte, Clermont-Ferrand

67033

Strasbourg - Icans, Strasbourg

69373

Centre Léon Bérard - Hématologie, Lyon

69495

Centre Hospitalier Lyon Sud, Pierre-Bénite

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

French Innovative Leukemia Organisation

OTHER

NCT05621148 - REfractorinesS to Ibrutinib BTKi and Systemic Targeted Therapy | Biotech Hunter | Biotech Hunter